Phase Ib Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Uveal Melanoma

Trial Profile

Phase Ib Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Uveal Melanoma

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Interleukin-2 (Primary) ; Ipilimumab (Primary) ; T cell replacement therapy (Primary)
  • Indications Uveal melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Jul 2017 Planned End Date changed from 1 Jun 2021 to 1 Aug 2021.
    • 03 Jul 2017 Planned primary completion date changed from 1 Jun 2021 to 1 Aug 2021.
    • 03 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top